Novo Nordisk says Wegovy cuts liver fat to normal levels in 88.5% of STEP UP trial subgroup by week 72

By Public Technologies
  • Novo Nordisk presented a post hoc analysis at EASD 2026 from the STEP UP program assessing Wegovy’s impact on liver health.
  • The analysis found most adults with obesity and elevated liver fat moved into the normal range during 72 weeks of treatment.
  • Results point to potential use in addressing fatty liver early in obesity, extending Wegovy’s value beyond weight loss.
  • Separate late-stage ESSENCE data cited in the release support a broader push for semaglutide in MASH treatment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010645OMX_____CNEWS_EN_GNW1001275510_en) on October 01, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.